Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-interventional, Multi-center, Retrospective Observational Study to Investigate the Effectiveness and Safety of Olostar Tab in Patients With Essential Hypertension and Dyslipidemia (ROSE Study)

NCT03009721 is registered in ClinicalTrials.gov with Daewoong Pharmaceutical Co. LTD. as lead sponsor.

NCT NCT03009721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03009721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-interventional, Multi-center, Retrospective Observational Study to Investigate the Effectiveness and Safety of Olostar Tab in Patients With Essential Hypertension and Dyslipidemia (ROSE Study)
Lead sponsor
Daewoong Pharmaceutical Co. LTD.
Phase
Observational
Overall status
Unknown status
Start date
August 31, 2016
Completion date
June 30, 2018
Enrollment
9,707 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemias, hypertension